KRAS and neoplasm: This study aimed to investigate the prognostic potential of <i>KRAS</i> G12, G13, and Q61 mutations present in circulating tumor DNA (ctDNA) prior to treatment initiation in localized PDAC using both standard depth (20,000x) and ultra-deep (≥100,000) sequencing.<h4>Methods</h4>Plasma samples were collected from 45 patients with non-metastatic PDAC prior to treatment start.